BLLN vs LH vs DGX Stock Comparison

BillionToOne, Labcorp Holdings and Quest Diagnostics Prices as of Nov 13, 2026 Peers: Industry group
BLLN BillionToOne, Inc.
$105.15 +7.4% 1M +17.4% 1Y
Market cap
$4.60B
P/E
100.1x
Revenue (TTM)
$436.87M
Div. yield
–
Diagnostic Labs Healthcare
3 wins
LH Labcorp Holdings Inc.
$370.59 +16.7% 1M +38.3% 1Y
Market cap
$30.24B
P/E
30.1x
Revenue (TTM)
$14.59B
Div. yield
–
Diagnostic Labs Healthcare
2 wins
DGX Quest Diagnostics Inc
$259.78 +11.3% 1M +38.5% 1Y
Market cap
$28.82B
P/E
25.5x
Revenue (TTM)
$11.84B
Div. yield
0.01%
Diagnostic Labs Healthcare
6 wins

Head to Head

11 decided of 12

Quest Diagnostics leads on 6 of the 12 questions below (Quest Diagnostics 6, BillionToOne 3, Labcorp Holdings 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBLLNLHDGXLeader
Larger companyMarket capitalisation $4.60B $30.24B $28.82B LH
Cheaper on earningsLower P/E, profitable companies only 100.1x 30.1x 25.5x DGX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 114.3x 21.5x 23.7x LH
Faster revenue growthRevenue growth, trailing twelve months +71.9% +6.0% +9.1% BLLN
More profitableNet margin, trailing twelve months 10.5% 6.9% 9.5% BLLN
Better return on capitalReturn on invested capital 6.9% 8.3% 9.9% DGX
Less leveragedLower net debt / EBITDA -9.1x 2.6x 2.1x BLLN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +17.4% +38.3% +38.5% DGX
Better 5-year returnAnnualised price return, 5 years — +7.7%/yr +11.6%/yr DGX
Less volatileAnnualised volatility, 1 year 91.9% 24.1% 23.8% DGX
Higher overall scoreMean of the five percentile scores vs peers 58/100 57/100 63/100 DGX

Percentile Scorecard

BLLNLHDGX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBLLNLHDGX
Valuation 22 #77 of 99 55 #45 of 99 61 #39 of 99
Growth 100 #1 of 89 36 #57 of 89 41 #53 of 89
Profitability 63 #35 of 92 71 #27 of 92 82 #17 of 92
Financial Health 96 #5 of 103 46 #56 of 103 61 #41 of 103
Shareholder Returns 7 #59 of 63 77 #15 of 63 68 #21 of 63
Overall 58 57 63
  • BLLN ranked among 103 companies in Healthcare Providers
  • LH ranked among 103 companies in Healthcare Providers
  • DGX ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBLLNLHDGXSPY
1 month +7.4%+16.7%+11.3% -2.0%
3 months +12.7%+16.5%+10.9% -2.8%
6 months +27.3%+48.0%+39.2% +2.0%
Year to date +28.5%+47.7%+49.7% +10.6%
1 year +17.4%+38.3%+38.5% +12.2%
3 years —+78.1%+94.2% +68.1%
3 years, per year —+21.2%+24.8% +18.9%
5 years —+45.1%+73.2% +61.4%
5 years, per year —+7.7%+11.6% +10.1%
10 years —+245.6%+218.9% +248.5%
10 years, per year —+13.2%+12.3% +13.3%

Risk

MeasureBLLNLHDGXSPY
Volatility, 1Y 91.9%24.1%23.8% 13.6%
Downside volatility, 1Y 104.0%21.5%18.5% 13.9%
Beta vs S&P 500, 1Y 1.360.38-0.04 1.00
Return / volatility, 1Y 0.191.591.62 0.90
Max drawdown, 5Y -50.8%-35.0%-30.3% -25.4%
From 52-week high -29.9%-0.5%0.0% -3.2%
52-week high $149.97$372.35$259.78 $779.14
52-week low $64.03$250.39$173.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBLLNLHDGX
P/E now vs peer median 108.2xmedian 22.4x 29.9xmedian 22.4x 25.3xmedian 22.4x
P/S now vs peer median 11.5xmedian 1.3x 2.1xmedian 1.3x 2.4xmedian 1.3x
EV/EBITDA now vs peer median 87.4xmedian 14.2x 16.2xmedian 14.2x 14.4xmedian 14.2x
P/FCF now vs peer median 147.7xmedian 19.0x 23.4xmedian 19.0x 20.8xmedian 19.0x
P/B now vs peer median 8.8xmedian 2.6x 3.4xmedian 2.6x 3.6xmedian 2.6x
PEG now vs peer median —median 0.84 1.72median 0.84 1.73median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBLLNLHDGX
Revenue $436.87M $14.59B $11.84B
Gross profit $311.95M $4.23B $3.92B
Operating income $44.69M $1.50B $1.72B
Net income $49.39M $1.00B $1.18B
Free cash flow $33.91M $1.29B $1.38B
R&D $66.47M – –
EPS (diluted) $0.86 $12.30 $10.08
Cash & equivalents $561.51M $261.80M $797.00M
Total debt $89.00M $6.03B $5.55B
Shares (diluted) 53.73M 81.60M 112.00M
Enterprise value $2.46B $28.33B $26.59B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBLLNLHDGX
P/E 108.2x 29.9x 25.3x
P/FCF 147.7x 23.4x 20.8x
P/Operating cash flow 104.5x 16.6x 14.6x
P/S 11.5x 2.1x 2.4x
P/B 8.8x 3.4x 3.6x
P/Tangible book 8.8x 5.9x 4.5x
EV/EBITDA 87.4x 16.2x 14.4x
EV/EBIT 101.5x 23.9x 19.3x
EV/Revenue 10.4x 2.5x 2.8x
EV/FCF 133.8x 27.9x 24.2x
EV/Operating cash flow 94.7x 19.8x 17.1x
PEG (3Y EPS CAGR) – 1.72 1.73

Growth

14 metrics
MetricBLLNLHDGX
Revenue growth (1Y) 71.9% 6.0% 9.1%
Revenue CAGR (3Y) – 6.6% 8.4%
Gross profit growth (1Y) 88.4% 8.0% 8.5%
Gross profit CAGR (3Y) – 8.2% 8.4%
Operating income growth (1Y) 844.7% 12.6% 12.5%
Operating income CAGR (3Y) – 19.7% 15.1%
Net income growth (1Y) 593.9% 17.4% 15.0%
Net income CAGR (3Y) – 14.9% 12.9%
EPS growth (1Y) 193.7% 20.4% 17.6%
EPS CAGR (3Y) – 17.4% 14.6%
Operating cash flow growth (1Y) 794.7% 0.6% 3.5%
Operating cash flow CAGR (3Y) – 9.0% 21.8%
Free cash flow growth (1Y) 934.5% -6.8% -1.3%
Free cash flow CAGR (3Y) – 8.2% 32.1%

Profitability

14 metrics
MetricBLLNLHDGX
Gross margin 71.4% 29.0% 33.1%
EBITDA margin 11.9% 15.1% 19.5%
Operating margin 10.2% 10.3% 14.6%
Pretax margin 11.4% 8.4% 12.6%
Net margin 10.5% 6.9% 9.5%
FCF margin 7.8% 8.8% 11.6%
Operating cash flow margin 11.0% 12.4% 16.5%
Return on equity 9.0% 11.5% 15.0%
Return on assets 6.6% 5.4% 6.9%
Return on invested capital 6.9% 8.3% 9.9%
Return on capital employed 6.5% 9.4% 11.3%
Asset turnover 0.6x 0.8x 0.7x
Cash conversion (OCF / net income) 1.0x 1.8x 1.7x
Stock comp / revenue 7.0% 0.9% 0.7%

Financial Health

11 metrics
MetricBLLNLHDGX
Debt / assets 11.7% 31.9% 32.2%
Debt / equity 0.2x 0.7x 0.7x
Net debt / EBITDA -9.1x 2.6x 2.1x
Debt / FCF 2.6x 4.7x 4.0x
Liabilities / assets 25.5% 53.2% 53.8%
Equity / assets 74.5% 46.8% 46.2%
Interest coverage 1,655x 6.5x 6.5x
Current ratio 11.2x 1.4x 1.7x
Quick ratio 10.7x 1.0x 1.4x
Cash ratio 9.3x 0.1x 0.4x
Altman Z-score 16.82 3.56 3.82

Shareholder Returns

7 metrics
MetricBLLNLHDGX
Dividend yield – 0.8% 1.3%
Net buyback yield -6.1% 2.0% 1.1%
Shareholder yield -6.1% 2.7% 2.4%
Payout ratio (earnings) – – 31.3%
Payout ratio (FCF) – – 26.8%
Dividend growth (1Y) – – 6.3%
Dividend CAGR (3Y) – – 6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBLLNLHDGX
Forward P/E 114.3xFY2026 21.5xFY2026 23.7xFY2026
EPS, next fiscal year $0.92FY2026 $17.22FY2026 $10.98FY2026
EPS growth, next FY +557.1%FY2026 +4.7%FY2026 +11.5%FY2026
EPS growth, the year after -2.2% +7.8% +6.6%
Revenue, next fiscal year $484.85MFY2026 $14.39BFY2026 $11.25BFY2026
Revenue growth, next FY +58.9%FY2026 +3.1%FY2026 +1.9%FY2026
Revenue growth, the year after +27.2% +12.5% +7.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBLLNLHDGX
Held by institutions 32.6% 97.0% 94.4%
Institutions holding 155 1,053 1,098
Change in shares held, QoQ +34.7% +1.6% +2.7%
Institutions buying 127 466 549
Institutions selling 13 393 342
Buyers to sellers 9.77 1.19 1.61

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BLLNLHDGX
BLLN 1.00 0.11 0.11
LH 0.11 1.00 0.72
DGX 0.11 0.72 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BLLN, LH and DGX?

Labcorp Holdings (LH) is the largest by market capitalisation: BillionToOne (BLLN) $4.60B, Labcorp Holdings (LH) $30.24B, Quest Diagnostics (DGX) $28.82B.

Which stock is cheaper, BLLN, LH and DGX?

Quest Diagnostics (DGX) trades on the lowest price-to-earnings ratio (BillionToOne (BLLN) 100.1x, Labcorp Holdings (LH) 30.1x, Quest Diagnostics (DGX) 25.5x). On next year's consensus earnings, Labcorp Holdings (LH) is cheapest (BillionToOne (BLLN) 114.3x, Labcorp Holdings (LH) 21.5x, Quest Diagnostics (DGX) 23.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

BillionToOne (BLLN) grew revenue fastest over the trailing twelve months: BillionToOne (BLLN) +71.9%, Labcorp Holdings (LH) +6.0%, Quest Diagnostics (DGX) +9.1%.

Which company is more profitable?

BillionToOne (BLLN) has the highest net margin (BillionToOne (BLLN) 10.5%, Labcorp Holdings (LH) 6.9%, Quest Diagnostics (DGX) 9.5%). On return on invested capital, Quest Diagnostics (DGX) leads (BillionToOne (BLLN) 6.9%, Labcorp Holdings (LH) 8.3%, Quest Diagnostics (DGX) 9.9%).

Which stock has performed better?

Over the past year Quest Diagnostics (DGX) returned the most: BillionToOne (BLLN) +17.4%, Labcorp Holdings (LH) +38.3%, Quest Diagnostics (DGX) +38.5%. Over five years, Quest Diagnostics (DGX) compounded fastest (Labcorp Holdings (LH) +7.7%/yr, Quest Diagnostics (DGX) +11.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: BillionToOne (BLLN) 0.00%, Labcorp Holdings (LH) 0.00%, Quest Diagnostics (DGX) 0.01%. BillionToOne (BLLN) and Labcorp Holdings (LH) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Quest Diagnostics (DGX) has been the steadiest (BillionToOne (BLLN) 91.9%, Labcorp Holdings (LH) 24.1%, Quest Diagnostics (DGX) 23.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BLLN, LH and DGX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Quest Diagnostics (DGX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.